Independent testing by Choice of sunscreen products has contributed to discussions on regulatory oversight in Australia, ahead of the Therapeutic Goods Administration (TGA) opening consultation on proposed reforms.
The TGA has initiated a consultation process seeking feedback on proposed changes to the regulation of therapeutic sunscreens. The review follows international and domestic developments, as well as Australia’s skin cancer burden, with around 2000 deaths each year.
SPF accuracy under review
In a recent assessment, Choice tested 20 sunscreen products across different price points to examine the accuracy of sun protection factor (SPF) claims. Testing was conducted at a TGA-approved laboratory. Results showed that 16 of the 20 products did not meet their stated SPF levels, with some products labelled SPF 50+ measuring SPF 4, and others measuring between SPF 20 and SPF 40.
Testing involved adult volunteers using standard procedures to assess protection against UVB radiation. Choice said the variation may lead to misinterpretation of protection duration and level.
Following the tests, Choice contacted manufacturers. Some companies disputed the findings and provided their own test data. Choice said it maintains its position, citing the use of a TGA-approved laboratory.
Ultra Violette stated that, based on zinc oxide content, an SPF result of 4 was not scientifically plausible. Choice conducted a further test using a new sample at a separate laboratory, which returned an SPF of 5. The product was later withdrawn after an internal review that included eight test results.
Choice reported its findings to both the TGA and the Australian Competition and Consumer Commission (ACCC), and called for increased independent compliance testing rather than reliance on manufacturer-submitted data.
Regulatory response
The consultation proposes measures to improve the reliability and transparency of SPF testing, strengthen oversight of testing laboratories, enhance lifecycle quality assurance, simplify SPF labelling, align indications for therapeutic and cosmetic sunscreens and update Good Manufacturing Practice guidance.
In response, Choice campaigns director Andy Kelly said the organisation supports proposals to revise testing requirements, laboratory accreditation and transparency measures, noting that these steps may help restore confidence in SPF labelling.
However, Choice said it does not support some options, including proposals to change the current SPF classification system. The organisation also noted that more than 20 sunscreen products were withdrawn from the market following its earlier investigation.
“Following Choice’s sunscreen investigation, over 20 sunscreens were pulled from sale in Australia due to concerns that they did not meet the SPF claims on their label,” Kelly said. “Without this investigation, it’s likely these products would still be available for sale.”
Choice said it will continue working with the TGA on sunscreen regulation and compliance.
Estimates indicate that two in three Australians will be diagnosed with a form of skin cancer during their lifetime.
